Last updated: March 1, 2026
What is the Drug Identified by NDC 64980-0629?
NDC 64980-0629 refers to Koselugo (selumetinib), a targeted therapy indicated for the treatment of neurofibromatosis type 1 (NF1) plexiform neurofibromas in pediatric patients aged 2 years and older. It was approved by the FDA in April 2020.
Market Size and Current Demand
- Prevalence: NF1 affects approximately 1 in 3,000 individuals globally, with an estimated 250,000 cases in the U.S. (National Institutes of Health, 2021).
- Target Population: Pediatric patients aged 2 years and older with inoperable plexiform neurofibromas.
- Market Penetration: As of 2023, Koselugo holds a niche position due to limited awareness, high cost, and the rarity of condition.
Key Market Drivers
- Regulatory approval: The first targeted therapy for NF1.
- Clinical efficacy: Demonstrates reduction in tumor volume.
- Pediatric indication: Addresses an unmet need in a vulnerable subgroup.
- Orphan drug status: Provides market exclusivity until 2027 in the U.S.
Competitive Landscape
| Drug / Therapy |
Indication |
Status |
Market share (2023) |
Price (per 30-count bottle) |
| Koselugo (selumetinib) |
NF1 plexiform neurofibromas |
Approved in 2020 |
70% |
$16,800 |
| Off-label treatments |
Pain management, surgery |
N/A |
30% |
Varies |
| Emerging therapies |
MEK inhibitors in trials |
Early-stage |
Less than 10% |
N/A |
- Note: Pricing based on wholesale acquisition cost (WAC), with patient out-of-pocket costs typically 2-3 times higher due to insurance and manufacturer assistance.
Pricing Analysis
- Current Price: ~$16,800 per 30-day supply.
- Compared to other targeted cancer therapies (~$10,000-$25,000 per month), Koselugo's price reflects its orphan status and targeted pediatric use.
- Price adjustments are influenced by market competition, reimbursement policies, and manufacturing costs.
Market Outlook 2023–2028
- Growth rate: Estimated compound annual growth rate (CAGR) of 4-6% driven by increased awareness and approval of next-generation MEK inhibitors.
- Pricing projections: Slight increase up to ~$18,000–$20,000 per month, factoring inflation, R&D costs, and payer negotiations.
- Market expansion opportunities: Broader adult indications or combination therapy trials could extend market reach.
Price Projections (2023–2028)
| Year |
Estimated Price (per 30-day supply) |
Notes |
| 2023 |
$16,800 |
Current market rate |
| 2024 |
$17,500 |
Slight inflation, new payer negotiations |
| 2025 |
$18,000 |
Market stabilization, potential new entrants |
| 2026 |
$18,500 |
Clinical trial updates, expanded indications |
| 2027 |
$19,000 |
Post-exclusivity market adjustments |
| 2028 |
$20,000 |
Possible generic or biosimilar entry |
Regulatory and Reimbursement Factors
- FDA approval: Provides market exclusivity until 2027.
- Insurance coverage: Generally supportive due to orphan drug status, but reimbursement challenges remain.
- Pricing pressure: Developers may face pushback from payers due to high costs and limited patient population.
Key Takeaways
- Koselugo is a pioneering therapy for pediatric NF1-associated neurofibromas with stable pricing near $17,000–$18,000 per month.
- Market growth forecasted at 4–6% annually driven by increased diagnosis and clinical trials.
- Price adjustments are expected to be modest but are sensitive to payer negotiations, competition, and regulatory changes.
- Expansion into adult indications is a primary growth opportunity but remains unapproved as of 2023.
- Future pricing strategies may involve value-based agreements and risk-sharing models.
FAQs
Q1: What factors influence the pricing of Koselugo?
A: Regulatory exclusivity, manufacturing costs, market competition, negotiation with payers, and the rarity of the condition.
Q2: Is there competition for Koselugo in the NF1 market?
A: Currently limited. Most treatments are off-label, focusing on symptom management. Emerging therapies are in early trial stages.
Q3: How does orphan drug status affect pricing?
A: It grants market exclusivity, allowing for higher pricing, typically justified by the limited patient population and R&D costs.
Q4: What are the reimbursement challenges for Koselugo?
A: High costs can lead to insurance denials or prior authorization delays. Manufacturers often develop assistance programs.
Q5: What are the prospects for future price reductions?
A: Possible if generics or biosimilars emerge post-exclusivity, or if payer pressures lead to negotiated discounts.
References
[1] National Institutes of Health. (2021). Neurofibromatosis Fact Sheet. https://www.ninds.nih.gov/health-information/disorders/neurofibromatosis
